Director CVRM Practice @ RAS LifeScience Solutions | Strategy | Competitive Intelligence | Data Analysis and Visualization
We attended the EMSO 2023 congress in Oct, at Madrid, during which we had the opportunity to learn about some of the recent advances in the field of cancer research, and also connect with some great minds! This year, >30,000 people attended the congress in person from >150 countries. Some of the "hot" topics that garnered a lot of attention were ADCs (antibody-drug conjugates) with several data readouts in late-breaking sessions such as 302/KEYNOTE-A39, TROPION-Breast01, DESTINY-PanTumor 01 etc. These molecules are anticipated to set new therapeutic standards. In addition to ADCs, lung cancer also took center stage during the conference with >25 sessions. Below is a crisp summary of the most notable topics that we captured during ESMO 2023 At RAS, we provide comprehensive conference coverage support across multiple therapeutic areas. If you would like to know more about our conference services or get hold of our conference reports, do reach out to us! Please like and share if you found the summary useful and comment below if you'd like us to send you a sample report. #oncology #cancerresearch #cancer #researchanddevelopment #conference #medicalconference #oncologyresearch #raslss #consultingservice #esmo2023 #esmo23
A recap of ESMO 2023: Let's revisit some of the significant and groundbreaking research presented at last month's ESMO conference in Madrid, Spain #esmo23 #raslss #oncology #oncologyresearch #competitiveintelligence #conferences #healthcare #rarediseases #cancerresearch #pharmaceutical #pharma
